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Abstract
Growing evidence suggests an elevated risk for colorectal neoplasia among individuals with low levels of vitamin D, the biological actions of 
which are mediated by the vitamin D receptor (VDR). To investigate the association among vitamin D status, VDR polymorphisms (FokI, and
BsmI), and colorectal adenoma, we conducted a meta-analysis of nine studies of circulating levels of 25-hydroxyvitamin D (25(OH)D) and five 
studies of FokI or BsmI polymorphisms in relation to colorectal adenomas. Study-specific relative risks (RRs) and 95% confidence intervals (CIs)
were pooled using a random-effects model. A total of 3398 colorectal adenomas for 25(OH)D and 1754 colorectal adenomas for VDR were included
in the meta-analysis. We identified a significant inverse association between colorectal adenoma (combined RR, 0.93; 95% CI, 0.87-0.98 per 10 
ng/mL increase in 25(OH)D levels). When we examined FokI and BsmI polymorphisms in the meta-analysis, we found no association for either 
FokI (combined RR, 1.00; 95% CI, 0.95-1.06) or BsmI (combined RR, 0.99; 95% CI, 0.93-1.05) in the additive model. These data suggest an
inverse association between circulating 25(OH)D levels and colorectal adenoma risk. 
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Introduction13)
Vitamin D decreases cancer risk by improving differentiation 
and apoptosis and decreasing proliferation, invasiveness, 
metastatic potential, and angiogenesis [1]. Vitamin D is produced 
by exposing the skin to ultraviolet radiation, which is required 
for conversion of 7-dehydrocholesterol into vitamin D (cholecal-
ciferol), which is then hydroxylated to 25-hydroxylvitamin D 
(25(OH)D) in the liver. This 25(OH)D is converted to 1,25- 
dihydroxyvitamin D (1,25(OH)2D) by 1-α-hydroxylase in the 
kidney [2] and other sites, including the colon [3]. 
The vitamin D receptor (VDR) binds to 1,25(OH)2D and 
interacts with target-cell nuclei; thus, mediating the biological 
actions of vitamin D [4]. Because of the potential importance 
of VDR in cancer etiology, the associations between variants of 
the VDR gene and colorectal cancer have been examined in 
several studies [5,6]. The most frequently studied single nucleotide 
polymorphisms are FokI (rs2228570) and BsmI (rs1544410). The 
FokI restriction fragment length polymorphism exhibits two 
isoform VDR proteins that may have different transcription 
efficiencies [7]; the presence of the restriction site produces the 
427-residue isoform (f-allele) of the VDR, whereas the absence 
of the restriction site results in the 424-residue isoform (F-allele), 
which may have higher transcriptional activity. The BsmI 
restriction site in the intron at the 3′-untranslated region of the 
VDR gene, which is strongly linked with polymorphisms in ApaI, 
TaqI, and poly(A) and does not change the encoded VDR protein, 
is associated with bone mineral density [8] and prostate cancer 
[9]. The B of BsmI denotes the absence of a restriction site, 
and b denotes the presence of a restriction site. 
Given the possible favorable effect of vitamin D against cancer, 
several epidemiological studies have suggested a possible increased 
risk for colorectal neoplasia with low vitamin D status [10] or 
with certain VDR gene alleles [5,6]. Several case-control and 
prospective studies found inverse or no associations between 
circulating vitamin D levels and colorectal adenoma [11-19]. We 
performed a meta-analysis of nine studies, including 3,398 cases 
and 3,883 controls, to examine whether circulating blood 25(OH) 
levels were inversely associated with colorectal adenoma, a 
precursor colorectal cancer lesion. We also examined the 
associations between common FokI and BsmI polymorphisms 
and colorectal adenoma in a meta-analysis of five studies for 
each polymorphism.
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Subjects and Methods
Identification and selection of studies 
We searched the PUBMED database for the period before 
January 2011 using the terms [(vitamin D [MeSH] and “vitamin 
D” or “25-hydroxyvitamin D”) and (“adenoma”)] and the 
EMBASE and MEDLINE databases using the terms [(“vitamin 
D” or “25-hydroxyvitamin D”) and (“adenoma”)] for circulating 
vitamin D levels and colorectal adenoma. The search was 
restricted to human studies reported in English-language articles. 
In total, 147 abstracts were identified in the PUBMED database 
and 48 from EMBASE and MEDLINE. We also examined 
references from these publications to identify further studies. For 
VDR, we searched the PUBMED, EMBASE, and MEDLINE 
databases for the period up to January 2011 using the terms 
[((“vitamin D receptor” or “Fok” or “Bsm”) and (“adenoma”)) 
or (“rs2228570” or “rs1544410”)]. The search was restricted to 
human studies reported in English-language articles. In total, 68 
abstracts were identified from the PUBMED database and 35 
from EMBASE and MEDLINE. We identified nine studies 
[11-19] that examined serum or plasma 25(OH)D and first 
colorectal adenoma or adenoma recurrence, and five studies for 
each polymorphism [15,16,20-24] that reported the associations 
between the FokI or BsmI polymorphisms and colorectal 
adenoma or adenoma recurrence and met the following criteria; 
1) serum or plasma 25(OH)D or VDR FokI or BsmI polymor-
phisms were assayed as the exposure of interest; 2) the outcome 
of interest was colorectal adenoma or adenoma recurrence; and 
3) the relative risk (RR) and 95% confidence intervals (CIs) were 
reported.
Statistical analysis
We extracted the RRs for a standard unit of increase in 
25(OH)D levels and the RRs comparing the top 25(OH)D 
categories with the bottom categories. To construct dose-response 
models if the RR per standard unit of increase was not reported, 
we fit a linear model to estimate the RRs per 10 ng/mL increase 
in circulating vitamin D levels using the method proposed by 
Greenland and Longnecker [25] and Orsini et al. [26]. For the 
common VDR polymorphisms FokI and BsmI, we considered 
the homozygous genotype of the more prevalent allele as the 
reference group (F for FokI and b for BsmI). We extracted the 
number of cases and controls for the crude combined RR to 
combine all studies and present the combined RRs in additive, 
dominant, and recessive models. We contacted the author of one 
study to obtain the RRs for FokI polymorphisms in dominant 
and recessive models, but were unable to obtain the data. For 
one study [16], which did not report the number of cases or 
controls by FokI polymorphism but did report the RRs with the 
reference group of the FF genotype, we used the RRs presented 
for the additive model but did not include that study for dominant 
and recessive models because of a lack of information. The 
results were similar when we compared the combined RRs of 
the adjusted estimates with the crude combined RR in four studies 
that reported the adjusted RRs comparing the homozygous 
genotype of variant type with the homozygous genotype of the 
wild type (data not shown). 
The summary RRs were estimated using a random effects 
model developed by DerSimonian and Laird [27]. The individual 
study estimates were weighted by the inverse of their variance. 
We tested for heterogeneity among studies using the Q statistic 
[27] and examined heterogeneity by type of study, country, or 
adjustment for season, body mass index (BMI), and physical 
activity across studies. Publication bias was assessed using the 
Egger regression asymmetry test [28]. All statistical analyses 
were performed with STATA 11 statistical software (StataCorp, 
College Station, TX, USA). A P < 0.05 (two sided) was 
considered statistically significant. 
Results
Circulating 25(OH)D levels and colorectal adenoma
Nine studies met the inclusion criteria for circulating vitamin 
D levels and colorectal adenoma (Table 1), including four 
prospective studies and five case-control studies. Among the four 
prospective studies, two were trials of adenoma recurrence 
(treatment reagents were ursodeoxycholic acid in one study [12] 
and calcium carbonate in the other study [16]), and the other 
two studies were prospective, which followed participants with 
updated information on sigmoidoscopy or colonoscopy. In the 
five case-control studies, blood samples of participants were 
collected at or after diagnosis of colorectal adenoma. Eight 
studies were conducted in multiple regions in the US, and one 
study was conducted in Japan. In total, 3,398 cases and 3,883 
controls were included in the meta-analysis of circulating 
25(OH)D levels and colorectal adenoma. Of the nine studies, 
time of blood draw (season, month, or date) was matched or 
adjusted in six studies [12-15,18,19], and BMI or physical 
activity was considered a confounding factor in seven studies 
[11-15,17,18]. Colorectal adenoma cases were ascertained mostly 
through colonoscopies in six studies. Five studies [11,15-17,19] 
reported estimates by calcium intake strata. 
We observed a significant inverse association between 25(OH)D 
levels and colorectal adenoma (combined RR, 0.93; 95% CI, 
0.87-0.98 per 10 ng/mL increase in 25(OH)D levels (Fig. 1). 
For a 20 ng/mL increase in 25(OH)D levels, the combined RR 
was 0.84 (95% CI, 0.73-0.96). When we compared top with 
bottom categories of 25(OH)D levels, the combined RR (95% 
CI) was 0.73 (0.54-0.92). To examine whether there was a 
tendency for investigators to publish positive findings, we explored 
asymmetry of a funnel plot. There was no evidence of publication 
bias at the 0.05 level (Egger’s test P= 0.07 for RRs per 10 ng/mL 466 Vitamin D and colorectal adenoma
First author, year 
[Ref no.] Country (Sex
1))  Study design Endpoint Type of endoscopy
Age at blood 
donation in controls 
(years)
No. of cases 
/ controls 25(OH)D, mean or median
Platz, 2000 [13] US (W) Prospective First adenoma Sigmoidoscopy or 
colonoscopy
58.5 in 1990, mean 326 / 326 26.4 in cases and 26.8 
ng/mL in controls, mean
Levine, 2001 [17] US (M, W) Case-control First adenoma Sigmoidoscopy 61.8, mean 473 / 506 25.6 in cases and 26.9 
ng/mL in controls, mean
Peters, 2001 [15] US (M, W) Case-control First (61%) or 
recurrent adenoma
Colonoscopy (86.2%) 
or sigmoidoscopy
57, median 236 / 218 24.7 in cases and 26.5 
ng/mL in controls, median
Grau, 2003 [16] US (M, W) Prospective Recurrent adenoma Colonoscopy 61, mean 376 / 422 29.1 ng/mL, median
Peters, 2004 [14] US (M, W) Prospective First adenoma Sigmoidoscopy 62.3, mean 394 / 397 27.0 in cases and 28.3 
ng/mL in controls, mean
Jacobs, 2007 [12] US (M, W) Prospective Recurrent adenoma Colonoscopy (97.7%) 
and sigmoidoscopy
2)
66.0, mean 210 / 358 26.9 ng/mL in men, and 
25.1 ng/mL in women, mean
Miller, 2007 [19] US (M, W) Case-control First adenoma Colonoscopy 54.4, mean 111 / 238 27.5 in cases and 31.4 
ng/mL in controls, mean
Takahashi, 2010 [18] Japan (M, W) Case-control First adenoma Colonoscopy 51.8, mean 656 / 648 26.2 in cases and 26.1 
ng/mL in controls, mean
Fedirko, 2010 [11] US (M,W) Case-control First adenoma Colonoscopy 53.6, mean 616 / 770 24.5 in cases and 25.5 
ng/mL in controls, mean
1) M ,  m e n ;  W ,  w o m e n
2) Information  was  obtained  from  Alberts  et  al.  [48].
Table 1. Included studies of circulating levels of 25(OH)D and risk of colorectal adenoma
Overall  (I-squared = 63.0%, p = 0.006)
Platz
Takahashi
Levine
Peters 2004
Grau
Fedirko
Miller
Jacobs
Peters 2001
Study
0.93 (0.87, 0.98)
0.96 (0.85, 1.08)
1.08 (0.97, 1.20)
0.96 (0.91, 1.01)
0.87 (0.75, 1.01)
0.99 (0.93, 1.06)
0.89 (0.79, 1.00)
0.60 (0.39, 0.94)
0.94 (0.83, 1.06)
0.74 (0.60, 0.92)
RR (95% CI)
0.93 (0.87, 0.98)
0.96 (0.85, 1.08)
1.08 (0.97, 1.20)
0.96 (0.91, 1.01)
0.87 (0.75, 1.01)
0.99 (0.93, 1.06)
0.89 (0.79, 1.00)
0.60 (0.39, 0.94)
0.94 (0.83, 1.06)
0.74 (0.60, 0.92)
RR (95% CI)
   1 .5 1 1.5
Fig. 1. Study-specific and combined relative risks (RRs) and 95% confidence 
intervals (CIs) of colorectal adenoma per 10 ng/mL increase in blood 25(OH)D 
levels. Black circles indicate the study-specific relative risks; horizontal lines 
represent the 95% CIs. The area of the gray squares reflects the study-specific 
weights (inverse of the variance). The dashed line represents the combined RR 
and the diamond represents the 95% CI for the combined RR. 
increase in 25(OH)D levels). We explored the heterogeneity in 
25(OH)D levels across colorectal adenoma studies using 
sensitivity analyses. After excluding the study conducted in Japan 
[18], the combined RR (95% CI) per 10 ng/mL increase in 
25(OH)D levels was 0.91 (0.86-0.97; P heterogeneity = 0.02). 
When we excluded one study [19], which did not consider the 
covariance estimate across exposure levels because it did not 
report the number of subjects [25,26], we found a combined RR 
of 0.94 (95% CI, 0.89-0.99) per 10 ng/mL increase in 25(OH)D 
levels. We pooled estimates only among studies that considered 
season and BMI or physical activity; combined RRs (95% CI) 
per 10 ng/mL increase in 25(OH)D levels were 0.89 (95% CI, 
0.79-1.00) and 0.93 (95% CI, 0.87-0.99), respectively. When we 
excluded two clinical trials of colorectal adenoma recurrence, the 
results were similar; the combined RR was 0.92 (95% CI, 
0.86-0.99) per 10 ng/mL increase in 25(OH)D levels. The 
combined RRs (95% CIs) were 0.96 (0.91-1.01) in a meta- 
analysis of four prospective studies and 0.89 (0.78-1.00) in a 
meta-analysis of five case-control studies.
We also examined whether the association varied by calcium 
status in five studies [11,15-17,19]. When we pooled estimates 
by calcium status (high vs. low), we observed combined RRs 
of 0.71 (95% CI, 0.50-0.92) for high calcium status and 0.91 
(95% CI, 0.75-1.06) for low calcium status. 
VDR polymorphisms (FokI and BsmI) and colorectal adenoma
We found five studies for each polymorphism (1754 cases for 
FokI and 1740 cases for BsmI) that met the inclusion criteria 
for common polymorphisms of FokI or BsmI in relation to 
colorectal adenoma occurrence or adenoma recurrence (Table 2). 
For FokI polymorphisms, the endpoints were colorectal adenoma 
recurrence in three studies and adenoma occurrence in two 
studies. For BsmI polymorphisms, one study [23] examined 
colorectal adenoma recurrences in a randomized clinical trial of 
calcium carbonate. 
We detected no association for the FokI polymorphisms; 
combined RRs (95% CIs) were 1.00 (0.95-1.06) in the additive 
model (five studies; Fig. 2), 1.04 (0.82-1.25) in the dominant 
model (three studies), and 0.86 (0.60-1.12) in the recessive model 
(three studies). For BsmI polymorphisms, combined RRs (95% 
CIs) were 0.99 (0.93-1.05) in the additive model (five studies), 
0.96 (0.84-1.09) in the dominant model (five studies), and 1.00 
(0.82-1.17) in the recessive model (five studies). Egger’s test 
showed no significant evidence of publication bias (P= 0.95 for Jung Eun Lee 467
(A) FokI and colorectal adenoma
Overall  (I-squared = 0.0%, p = 0.643)
Grau
Egan
Study
Peters 2001
Ingles
Hubner
1.00 (0.95, 1.06)
1.03 (0.94, 1.13)
0.93 (0.80, 1.09)
OR (95% CI)
1.10 (0.92, 1.33)
0.97 (0.86, 1.10)
1.01 (0.85, 1.21)
1.00 (0.95, 1.06)
1.03 (0.94, 1.13)
0.93 (0.80, 1.09)
OR (95% CI)
1.10 (0.92, 1.33)
0.97 (0.86, 1.10)
1.01 (0.85, 1.21)
   1 .5 1 1.5
(B) BsmI and colorectal adenoma
Overall  (I-squared = 0.0%, p = 0.668)
Hubner
Kim
Egan
Boyapati
Ingles
Study
0.99 (0.93, 1.05)
0.99 (0.83, 1.17)
0.92 (0.82, 1.04)
1.01 (0.87, 1.18)
1.06 (0.90, 1.25)
1.03 (0.91, 1.16)
OR (95% CI)
0.99 (0.93, 1.05)
0.99 (0.83, 1.17)
0.92 (0.82, 1.04)
1.01 (0.87, 1.18)
1.06 (0.90, 1.25)
1.03 (0.91, 1.16)
OR (95% CI)
   1 .5 1 1.5
Fig. 2. Study-specific and combined relative risks (RRs) and 95% confidence 
intervals (CIs) for colorectal adenoma according to FokI and BsmI 
polymorphisms in the additive model. Black circles indicate study-specific odds 
ratios; horizontal lines represent the 95% CIs. The area of the gray squares 
reflects the study-specific weights (inverse of the variance). The dashed line 
represents the combined RR and the diamond represents the 95% CI for the 
combined RR. 
First author, year
(Ref no.)
Country
(Sex
1)) Ethnicity MAF
2) in 
controls Endpoint Type of endoscopy No. of cases 
/ non-cases
FokI
RR (95% CI)
BsmI
RR (95% CI)
Kim, 2001 [20] US (M, W) 97% of Caucasian
3) 0.43 for BsmI First adenoma Colonoscopy 393 / 406 - 0.71 (0.46-1.11) for 
BB vs. bb
Ingles, 2001 [21]  US (M, W) 57% of non-Hispanic 
white in controls
0.40 for FokI
0.37 for BsmI
First adenoma Sigmoidoscopy 373 / 394 0.94 (0.60-1.5) for 
ff vs. FF
1.1 (0.73-1.8) for 
BB vs. bb
Peters, 2001 [15] US (M, W) 89% of non-Hispanic 
white in controls
0.35 for FokI First or recurrent 
adenoma
Colonoscopy (86.2%) 
or sigmoidoscopy
208 / 184 0.75 (0.36-1.58) for 
FF vs. ff
-
Boyapati, 2003 [22] US (M, W) 90.2% of Caucasian 
in controls
0.45 for BsmI First adenoma Colonoscopy 177 / 228 - 0.87 (0.53-1.45) for 
bb vs. BB
Grau, 2003 [16] US (M, W) 84% of Caucasian 0.36 for FokI
4) Recurrent 
adenoma
Colonoscopy 376 / 422 1.06 (0.86-1.32) for 
ff vs. FF
-
Hubner, 2008 [23] UK (M, W) 100% Caucasian 0.38 for FokI
0.40 for BsmI
Recurrent 
adenoma
Colonoscopy 137 / 409 0.92 (0.58-1.46) for 
ff vs. FF
1.07 (0.73-1.57) for 
BB vs bb
Egan, 2010 [24] US (M, W) 95% of Caucasian N/A Recurrent 
adenoma
Colonoscopy
5) 660 / 779 0.93 (0.80-1.09) in 
additive model
1.01 (0.87-1.18) in 
additive model
1) M ,  m e n ;  W ,  w o m e n
2) Minor  allele  frequency
3) We  obtained  information  on  ethnicity  from  Smith-Warner  et  al. [ 4 9 ] .
4) Among  all  participants
5) We  obtained  information  on  type  of  endoscopy  from  Alberts  et  al. [ 5 0 ] a n d  A l b e r t s  et  al. [ 4 8 ] .
Table 2. Included studies of vitamin D receptor polymorphisms (FokI and BsmI) and risk of colorectal adenoma
FokI and P = 0.53 for BsmI in the additive model). We also 
pooled adjusted RRs shown in the articles; the combined RR 
(95% CI) was 1.02 (0.84-1.21) for ff vs. FF genotype of FokI 
and 0.93 (0.71-1.15) for BB vs. bb of BsmI in four studies. 
Discussion
We found an inverse association between circulating vitamin 
D levels and the risk for colorectal adenoma. However, we did 
not observe any associations between common FokI and BsmI 
polymorphisms and colorectal adenoma in this meta-analysis.
The hypothesis that vitamin D may prevent colorectal neoplasia 
has been supported by both experimental evidence and summaries 
of epidemiological studies on circulating vitamin D levels. 
Vitamin D may reduce the risk of colorectal neoplasia by regulating 
progression and differentiation [1] and inhibiting angiogenesis 
[29]. This hypothesis is supported by animal studies showing 
that vitamin D (the vitamin D3 analogue EB 1,089) improves 
tumor control following radiation treatment, possibly by 
promoting apoptosis [30]. Based on the geographic distribution 
of colon cancer mortality rates in the US, with the highest rates 
in regions with the least amount of sunlight, Garland and Garland 
hypothesized that vitamin D protects against colon cancer [31]. 
A recent systematic review of serum or plasma 25(OH)D levels 
and colorectal cancer incidence reported a 34% lower risk of 
colorectal cancer among individuals in the top quintiles compared 
to those in the bottom quintiles [32], which agrees with our 
meta-analysis results for colorectal adenoma. A previous 
meta-analysis of seven circulating vitamin D level and colorectal 
adenoma studies showed a RR of 0.70 (95% CI, 0.56-0.87) by 
comparing the highest with lowest quintile of 25(OH)D levels 
[33]. When we included two more studies [11,18], we found a 
7% decreased risk for colorectal adenoma per 10 ng/mL increase 468 Vitamin D and colorectal adenoma
in 25(OH)D levels, and our results were robust in multiple 
sensitivity analyses. Our meta-analysis results of five calcium 
status studies suggested that calcium and vitamin D may interact 
in the development of colorectal adenoma, which has been the 
subject of several previous studies with inconsistent findings 
[34-37]. This warrants further study. Given the high prevalence 
of vitamin D insufficiency in Korea [38], US, and Canada [39], 
the role of vitamin D in chronic disease development may merit 
priority for future research. 
The cellular effects of 1,25(OH)2D are mediated
  primarily 
through binding to the nuclear VDR, which
  regulates the transcrip-
tion of numerous genes, including protooncogenes
  and tumor 
suppressor genes [40]. Normal epithelial colon cells and cancer 
cells express VDR [41]. Epidemiological studies have examined 
the association between VDR polymorphisms and colorectal 
cancer, because of great interest in the preventive effect of 
vitamin D in relation to cancer at several sites [10]. The most 
frequently assessed genotypes are FokI and BsmI. However, a 
meta-analysis of FokI and BsmI and colorectal cancer incidence 
yielded no significant associations [6]. Our meta-analysis of 
colorectal adenoma also showed no association with FokI or 
BsmI polymorphisms. Previous studies have reported inconsistent 
findings for other VDR polymorphisms in relation to colorectal 
adenoma or cancer [14,23,24,42-45]. 
Each study relied upon a single measure of plasma vitamin 
D metabolite levels, which did not allow us to examine changes 
across time. However, a single measure of vitamin D metabolites 
is a useful marker for long-term vitamin D status [46,47]. 
Although we cannot rule out residual or unmeasured confounding 
factors, the combined estimates from studies that controlled for 
season, BMI, or physical activity still showed significant or 
marginally significant inverse associations, suggesting that our 
results may not be entirely explained by bias due to confounding 
factors. The combined adjusted RRs (when available) also 
showed no association for FokI or BsmI polymorphisms, which 
is in agreement with the combined crude RRs. The heterogeneity 
we found across studies in the meta-analysis may be due to 
differences in laboratory measurement methods, follow-up periods, 
seasons of blood draw, exposure to sunlight, ethnicity, or the 
prevalence of interaction factors and unknown/unmeasured con-
founding factors. The majority of our population was Caucasian 
for the combined estimates of VDR polymorphisms; thus this 
result is not generalizable to other populations. 
In summary, our meta-analysis found a significant inverse 
association between 25(OH)D levels and colorectal adenoma. No 
significant association between FokI or BsmI polymorphisms and 
colorectal adenoma was detected. Further prospective studies or 
randomized clinical trials of vitamin D in relation to colorectal 
neoplasia and other VDR gene polymorphisms may be necessary.
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